首页> 外文期刊>Open access Journal of Contraception >A novel medical protocol to treat uterotubal spasm during Essure hysteroscopic sterilization: a pilot study
【24h】

A novel medical protocol to treat uterotubal spasm during Essure hysteroscopic sterilization: a pilot study

机译:宫腔镜绝育术治疗子宫输卵管痉挛的新医学方案:一项初步研究

获取原文
           

摘要

Objective: To evaluate sublingual hyoscyamine (0.125 mg) as a uterotubal spasm reliever to increase successful bilateral, first-attempt Essure microinsert placement.Study design: Prospective cohort study as pilot clinical investigation of study medicine.Setting: An inner-city Dallas, TX obstetrics and gynecology office practice.Materials and methods: The study period was January 1, 2008 to July 1, 2010. Patients requesting sterilization were offered Essure under local anesthesia (office setting). Those declining were referred for operative laparoscopy. Patients accepting office sterilization were offered study participation. Study patients noted to have intraoperative uni/bilateral uterotubal spasms preventing cannulation were given one sublingual hyoscyamine (0.125 mg) tablet. Primary endpoint: spasm alleviation and successful tubal cannulation (bilaterally). Secondary endpoint: percentage of bilateral tubal occlusions documented by follow up hysterosalpingogram (12 weeks), and adverse events possibly related to medication.Results: Within the study period, 316 patients underwent office sterilization (local anesthesia); 21 had unilateral tubal spasm preventing cannulation (6%). Spasm was relieved in 17/21 (80%) after hyoscyamine, allowing for microinsert placement. The mean time from attempted cannulation to medication was 9 minutes (8.3–10.5 minutes), and the mean time for spasm resolution was 53 seconds (49–72 seconds). At follow-up confirmation testing, all 17 who were hyoscynamine responders were found to have bilateral tubal occlusion as well as proper microinsert location. The 4/21 hyoscyamine nonresponders underwent a second unilateral attempt 48–72 hours later. Fifty percent (n = 2) had successful placement, leaving two for alternative care. Rapid pulse was reported by 1/21 (4.7%) 5 minutes postmedication.Conclusion: Essure sterilization has a high bilateral, first-attempt success rate. Hyoscyamine may aid in spasm relief and increase single procedure, bilateral placement success rate further.
机译:目的:评估舌下含硫磺胺(0.125 mg)作为子宫输卵管痉挛缓解剂,以增加成功的双边,首次尝试的Essure微插入疗法的研究设计:前瞻性队列研究作为研究药物的临床试验研究环境:德克萨斯州达拉斯市中心材料和方法:研究时间为2008年1月1日至2010年7月1日。对要求绝育的患者在局部麻醉(办公室环境)下给予Essure。那些下降的患者被推荐进行腹腔镜手术。为接受办公室绝育的患者提供研究参与。对研究中发现患有术中单/双侧子宫输卵管痉挛预防插管的患者,给予一种舌下含糖扁桃碱(0.125 mg)片剂。主要终点:缓解痉挛和成功进行输卵管插管(双侧)。次要终点:随访子宫输卵管造影记录的双侧输卵管阻塞百分比(12周)以及可能与药物治疗相关的不良事件。结果:在研究期内,有316例患者接受了办公室绝育(局部麻醉)。 21例单侧输卵管痉挛预防插管(6%)。接种丝胺后,痉挛缓解率达17/21(80%),可进行微插入。从尝试插管到服药的平均时间为9分钟(8.3–10.5分钟),解决痉挛的平均时间为53秒(49–72秒)。在随访确认测试中,发现所有17位硫辛胺反应者均患有双侧输卵管阻塞以及正确的微插入位置。 4/21羟乙胺无反应者在48-72小时后进行了第二次单方面尝试。 50%(n = 2)成功放置,剩下2人需要替代护理。服药后5分钟,有1/21(4.7%)的患者出现快速脉搏。结论:保证绝育具有较高的双侧,首次尝试成功率。羟乙胺可能有助于缓解痉挛,增加单次手术,进一步增加双侧的成功率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号